{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:44:51Z","timestamp":1782733491053,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health and Sanitation Research Project of the Metallurgical Safety and Health Branch of the Chinese Society for Metals","award":["jkws202428"],"award-info":[{"award-number":["jkws202428"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"DOI":"10.1186\/s13019-026-04056-2","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:53:05Z","timestamp":1782730385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent lung cancer with multi-organ metastases showing remarkable regression after two weeks of targeted therapy: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Yalan","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoling","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"12","key":"4056_CR1","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.annonc.2024.10.006","volume":"35","author":"M ML","year":"2024","unstructured":"Meyer ML, Peters S, Mok TS, et al. Lung cancer research and treatment: global perspectives and strategic calls to action[J]. Annals oncology: official J Eur Soc Med Oncol. 2024;35(12):1088\u2013104.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"186","key":"4056_CR2","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1016\/j.wneu.2024.03.139","volume":"2024","author":"T Suzuki","year":"2024","unstructured":"Suzuki T, Deguchi S, Matsushima K, et al. Brain metastasis of non-small cell lung cancer after disease-free survival of 5 years: case series and comprehensive literature review. World Neurosurg. 2024;2024(186):e353\u20139.","journal-title":"World Neurosurg"},{"issue":"3","key":"4056_CR3","volume":"13","author":"LP V","year":"2021","unstructured":"Vemireddy LP, Jain N, Aqeel A, et al. Lung adenocarcinoma presenting as malignant pericardial effusion\/tamponade. Cureus. 2021;13(3):e13762.","journal-title":"Cureus"},{"issue":"30(9)","key":"4056_CR4","first-page":"5021","volume":"2020","author":"A D","year":"2020","unstructured":"Dormieux A, Mezquita L, Cournede PH, et al. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. Eur Radiol. 2020;2020(30(9)):5021\u20138.","journal-title":"Eur Radiol"},{"issue":"7","key":"4056_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/oncolo\/oyae107","volume":"29","author":"AEB C","year":"2024","unstructured":"Chang AEB, Piper-Vallillo AJ, Mak RH, et al. The ASCENT trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist. 2024;29(7):609\u201318.","journal-title":"Oncologist"},{"issue":"2","key":"4056_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","volume":"22","author":"F Z","year":"2025","unstructured":"Zhou F, Guo H, Xia Y, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025;22(2):95\u2013116.","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"4056_CR7","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.24.00071","volume":"42","author":"B CM","year":"2024","unstructured":"Blakely CM, Urisman A, Gubens MA, et al Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study[J]. J Clin oncology: official J Am Soc Clin Oncol. 2024;42(26):3105\u201314.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"0923\u20137534","key":"4056_CR8","doi-asserted-by":"publisher","first-page":"S1589","DOI":"10.1016\/j.annonc.2022.10.415","volume":"33","author":"H Lv","year":"2022","unstructured":"Lv H, Jiao C, Zhou F, et al. 377P Aumolertinib as second-line therapy in T790M-positive or-negative patients with EGFR-mutated non-small cell lung cancer (NSCLC): A retrospective study[J]. Ann Oncol. 2022;33(0923\u20137534):S1589.","journal-title":"Ann Oncol"},{"issue":"5","key":"4056_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-022-01695-2","volume":"82","author":"M S","year":"2022","unstructured":"Shirley M, Keam SJ. Aumolertinib: a review in non-small cell lung cancer. Drugs. 2022;82(5):577\u201384.","journal-title":"Drugs"},{"issue":"1","key":"4056_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41698-025-00838-4","volume":"9","author":"G Middleton","year":"2025","unstructured":"Middleton G, Robbins HL, Fletcher P, et al. A phase II trial of mTORC1\/2 inhibition in STK11 deficient non small cell lung cancer[J]. NPJ precision Oncol. 2025,9(1):67.","journal-title":"NPJ precision Oncol"},{"issue":"1422\u20130067","key":"4056_CR11","doi-asserted-by":"publisher","first-page":"12402","DOI":"10.3390\/ijms252212402","volume":"25","author":"M Roszkowska","year":"2024","unstructured":"Roszkowska M. Multilevel Mechanisms of Cancer Drug Resistance[J]. Int J Mol Sci. 2024;25(1422\u20130067):12402.","journal-title":"Int J Mol Sci"},{"issue":"8056","key":"4056_CR12","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","volume":"639","author":"MA Bakir","year":"2025","unstructured":"Bakir MA, Reading JL, Gamble S, et al. Clonal driver neoantigen loss under EGFR TKI and immune selection pressures[J]. Nature.2025,639(8056):1052-1059.","journal-title":"Nature"},{"key":"4056_CR13","doi-asserted-by":"publisher","first-page":"A697","DOI":"10.1136\/jitc-2024-SITC2024.0606","volume":"0","author":"A Lisberg","year":"2024","unstructured":"Lisberg A, Liu B, Oh MS, et al. 606 Phase I trial of in situ vaccination with autologousCCL21gene-modified dendritic cells (CCL21-DC) combined with pembrolizumab for metastatic NSCLC[J]. Regul Young Investigator Award Abstracts. 2024;0:A697.","journal-title":"Regul Young Investigator Award Abstracts"},{"key":"4056_CR14","doi-asserted-by":"crossref","unstructured":"Shi Y, Wu L, Ji Y, et al. Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial[J]. The Lancet. Respiratory medicine. 2025;13(8):677-686.","DOI":"10.1016\/S2213-2600(25)00121-3"},{"key":"4056_CR15","doi-asserted-by":"crossref","unstructured":"Shi Y, Guo Y, Li X, et al. Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study[J]. Lancet Respiratory Med, 2025,13(4):327\u201337.","DOI":"10.1016\/S2213-2600(24)00417-X"},{"key":"4056_CR16","doi-asserted-by":"crossref","unstructured":"Zheng C, Ren Y, Wang K, et al. Comparison and Analysis of the Drug-Resistance Mechanism of Osimertinib- and Almonertinib-Resistant Cell Lines[J]. Analytical cellular pathology (Amsterdam), 2025,2025:5578693.","DOI":"10.1155\/ancp\/5578693"},{"issue":"0008\u20135472","key":"4056_CR17","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1158\/1538-7445.AM2023-3361","volume":"83","author":"FGD Olio","year":"2023","unstructured":"Olio FGD, Vasseur D, Garcia C, et al. Abstract 3361: Clinical and genomic correlates of liquid biopsy (LB) derived variant allele frequency (VAF) in advanced NSCLC patients[J]. Cancer Res. 2023;83(0008\u20135472):3361.","journal-title":"Cancer Res"},{"issue":"2059\u20137029","key":"4056_CR18","doi-asserted-by":"publisher","first-page":"101865","DOI":"10.1016\/j.esmoop.2023.101865","volume":"8","author":"ST Riva","year":"2023","unstructured":"Riva ST, Ogliari FR, Cangi MG, et al. 55P EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib[J]. ESMO Open. 2023;8(2059\u20137029):101865.","journal-title":"ESMO Open"},{"key":"4056_CR19","doi-asserted-by":"crossref","unstructured":"Lu S, Dong X, Jian H, et al. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)[J]. Cancer communications (London, England), 2024,44(9):1005\u201317.","DOI":"10.1002\/cac2.12594"},{"key":"4056_CR20","doi-asserted-by":"crossref","unstructured":"Chen H, Sun L, Yang Z, et al. Prognostic Factors in Postoperative Brain Metastases Derive From Non-small Cell Lung Cancer: A Retrospective Analysis[J]. Clin Med Insights Oncol, 2024,18:1383425492.","DOI":"10.1177\/11795549241304532"},{"issue":"1556\u20130864","key":"4056_CR21","first-page":"205","volume":"16","author":"X Le","year":"2020","unstructured":"Le X, Nilsson MB, Goldman JW, et al. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC[J]. J Thorac oncology: official publication Int Association Study Lung Cancer. 2020;16(1556\u20130864):205\u201315.","journal-title":"J Thorac oncology: official publication Int Association Study Lung Cancer"},{"key":"4056_CR22","first-page":"0","volume":"0","author":"JR Tonra","year":"2023","unstructured":"Tonra JR, Deevi DS, Corcoran E, et al. Data from Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy[Supplemental material]. American Association for Cancer Research. https:\/\/doi.org\/10.1158\/1078-0432.c.6518436IF","journal-title":"null"},{"key":"4056_CR23","first-page":"0","volume":"0","author":"JR Tonra","year":"2023","unstructured":"Tonra JR, Deevi DS, Corcoran E, et al. Supplement for Statistical Methods from Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy[Supplemental material]. American Association for Cancer Research. https:\/\/doi.org\/10.1158\/1078-0432.22441347.v1IF","journal-title":"null"},{"key":"4056_CR24","doi-asserted-by":"crossref","unstructured":"Zhang J, Wang S, Guo X, et al. Arginine Supplementation Targeting Tumor-Killing Immune Cells Reconstructs the Tumor Microenvironment and Enhances the Antitumor Immune Response[J]. ACS Nano, 2022,16(1936\u2009\u2013\u20090851):12964\u201378.","DOI":"10.1021\/acsnano.2c05408"},{"issue":"6","key":"4056_CR25","first-page":"3453","volume":"16","author":"L Qin","year":"2024","unstructured":"Qin L, Liang T, Zhu X, et al. Senescent Macrophages and the Lung Cancer Microenvironment: A New Perspective on Tumor Immune Evasion[J]. Aging disease. 2024,16(6):3453-3465.","journal-title":"Aging disease"},{"issue":"1","key":"4056_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"Z Lim","year":"2019","unstructured":"Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy[J]. J Hematol Oncol. 2019,12(1):134.","journal-title":"J Hematol Oncol"},{"issue":"1474\u2013175X","key":"4056_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","volume":"22","author":"M Labrie","year":"2022","unstructured":"Labrie M, Brugge JS, Mills GB, et al. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer[J]. Nat Rev Cancer. 2022;22(1474\u2013175X):323\u201339.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4056_CR28","doi-asserted-by":"publisher","first-page":"101179","DOI":"10.1016\/j.jpha.2024.101179","volume":"15","author":"J C","year":"2025","unstructured":"Jiang C, Xie S, Jia K, Feng G, et al. Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies[J]. J Pharm Anal. 2025;15(5):101179.","journal-title":"J Pharm Anal"},{"key":"4056_CR29","doi-asserted-by":"crossref","unstructured":"Petrella F, Cara A, Cassina EM, et al. Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement[J]. Cancers, 2025,17(11).","DOI":"10.3390\/cancers17111844"},{"issue":"12","key":"4056_CR30","doi-asserted-by":"publisher","first-page":"12996","DOI":"10.1002\/cam4.5972","volume":"12","author":"TY D Z","year":"2023","unstructured":"Zhou D, Yao T, Huang X, et al. Real-world comprehensive diagnosis and Surgery\u2009+\u2009X treatment strategy of early-stage synchronous multiple primary lung cancer[J]. Cancer Med. 2023;12(12):12996\u20133006.","journal-title":"Cancer Med"},{"key":"4056_CR31","doi-asserted-by":"crossref","unstructured":"Wienke S, Gordon S, Liang S, et al. Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for quantification of tumor fraction (TF) and association with outcomes from RADIOHEAD real-world advanced pan-cancer cohort.[J]. JOURNAL OF CLINICAL ONCOLOGY; 2024. 42(0732-183X):2570.","DOI":"10.1200\/JCO.2024.42.16_suppl.2570"},{"issue":"0008\u20135472","key":"4056_CR32","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1158\/1538-7445.AM2024-2490","volume":"84","author":"S Wienke","year":"2024","unstructured":"Wienke S, Gordon S, Liang S, et al. Abstract 2490: Quantification of tumor fraction and outcomes association in a real-world non-small cell lung cancer (NSCLC) cohort using a tissue agnostic epigenomic circulating tumor DNA (ctDNA) assay[J]. Cancer Res. 2024;84(0008\u20135472):2490.","journal-title":"Cancer Res"},{"issue":"0923\u20137534","key":"4056_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.annonc.2023.01.011","volume":"34","author":"T Mok","year":"2023","unstructured":"Mok T, Lopes G, Cho BC, et al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC[J]. Annals oncology: official J Eur Soc Med Oncol. 2023;34(0923\u20137534):377\u201388.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"key":"4056_CR34","doi-asserted-by":"crossref","unstructured":"Adib E, Nassar A, Kwiatkowski DJ, et al. PD-L1, tumor mutational burden (TMB) and long-term survival in patients with non-small cell lung cancer (NSCLC) and brain metastases.[J]. JOURNAL OF CLINICAL ONCOLOGY; 2024. 42(0732-183X):2034.","DOI":"10.1200\/JCO.2024.42.16_suppl.2034"},{"issue":"0923\u20137534","key":"4056_CR35","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.annonc.2024.06.014","volume":"35","author":"A Di Federico","year":"2024","unstructured":"Di Federico A, Alden S, Smithy JW, et al. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer[J]. Annals oncology: official J Eur Soc Med Oncol. 2024;35(0923\u20137534):902\u201313.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04056-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-04056-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04056-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:53:17Z","timestamp":1782730397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13019-026-04056-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4056"],"URL":"https:\/\/doi.org\/10.1186\/s13019-026-04056-2","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images. All team members and project leaders have signed relevant confidentiality agreements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"patient gave written informed consent for their personal or clinical details along with any identifying images to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"448"}}